Abbott, Pfizer Partner on Companion Dx for Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott yesterday said that it will partner with Pfizer on a molecular diagnostic test to screen non-small cell lung cancer tumors for the presence of gene rearrangements.

Pfizer is developing a drug that selectively targets cancer-causing genes implicated in the progress of many cancers, the firms said in a statement. For patients to be eligible to receive the drug candidate, a particular genetic translocation known to be present in NSCLC tumors and others cancers, but not in normal cells, must be identified in the tumor sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.